Potentials of N-Acyl Hydrazones Against Colorectal Cancer: A Mini Review.

IF 3 4区 医学 Q3 CHEMISTRY, MEDICINAL Anti-cancer agents in medicinal chemistry Pub Date : 2025-01-01 DOI:10.2174/0118715206356253241223040825
Darna Mounika, Sai Satya Sri Pulla, Swapnil Anil Sule, Vidya Jyothi Alli, Surender Singh Jadav
{"title":"Potentials of N-Acyl Hydrazones Against Colorectal Cancer: A Mini Review.","authors":"Darna Mounika, Sai Satya Sri Pulla, Swapnil Anil Sule, Vidya Jyothi Alli, Surender Singh Jadav","doi":"10.2174/0118715206356253241223040825","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a malignant gastrointestinal tract disorder with high occurrence and mortality index and showing an upsurge. Standard therapies for treating CRC are surgery and chemotherapy. Despite great effort in developing effective treatments, the progress is limited due to its relapse and recurrence. Prognosis of metastatic CRC is always complicated. This condition can be evaded by a novel approach i.e., targeted therapy which increases the survival rate in CRC patients by blocking important pathways and acting on immune checkpoints. Drugs with N-acyl hydrazones (NAH) are currently being employed treatment of infectious diseases and disorders. NAH in combination with diverse heterocycles, natural product isolates are identified as interesting CRC inhibitors under-explored. This review provides an overview of the existing CRC targeted compounds having acyl hydrazones, hydrazine, hydrazides moieties, and their underlying mechanisms towards different CRC cell lines, together with a discussion of their limitations and future trends.</p>","PeriodicalId":7934,"journal":{"name":"Anti-cancer agents in medicinal chemistry","volume":" ","pages":"1273-1286"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer agents in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118715206356253241223040825","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer (CRC) is a malignant gastrointestinal tract disorder with high occurrence and mortality index and showing an upsurge. Standard therapies for treating CRC are surgery and chemotherapy. Despite great effort in developing effective treatments, the progress is limited due to its relapse and recurrence. Prognosis of metastatic CRC is always complicated. This condition can be evaded by a novel approach i.e., targeted therapy which increases the survival rate in CRC patients by blocking important pathways and acting on immune checkpoints. Drugs with N-acyl hydrazones (NAH) are currently being employed treatment of infectious diseases and disorders. NAH in combination with diverse heterocycles, natural product isolates are identified as interesting CRC inhibitors under-explored. This review provides an overview of the existing CRC targeted compounds having acyl hydrazones, hydrazine, hydrazides moieties, and their underlying mechanisms towards different CRC cell lines, together with a discussion of their limitations and future trends.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
n -酰基腙类化合物抗结直肠癌的潜力综述
结直肠癌(Colorectal cancer, CRC)是一种发病率和死亡率高且呈上升趋势的恶性胃肠道疾病。治疗结直肠癌的标准疗法是手术和化疗。尽管在开发有效的治疗方法方面付出了巨大的努力,但由于其复发和复发,进展有限。转移性结直肠癌预后复杂。这种情况可以通过一种新的方法来避免,即靶向治疗,通过阻断重要途径和作用于免疫检查点来提高CRC患者的生存率。含有n -酰基腙(NAH)的药物目前被用于治疗感染性疾病和疾病。NAH与多种杂环化合物结合,天然产物分离物被认为是尚未开发的有趣的CRC抑制剂。本文综述了现有的具有酰基腙、肼、肼基团的结直肠癌靶向化合物,以及它们对不同结直肠癌细胞系的潜在机制,并讨论了它们的局限性和未来趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Anti-cancer agents in medicinal chemistry
Anti-cancer agents in medicinal chemistry ONCOLOGY-CHEMISTRY, MEDICINAL
CiteScore
5.10
自引率
3.60%
发文量
323
审稿时长
4-8 weeks
期刊介绍: Formerly: Current Medicinal Chemistry - Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents. Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication. Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.
期刊最新文献
Fungal β-D-Glucans: Versatile Agents in Immune Modulation, Tumor Suppression, and Nanomedicine Advances. Hyperthermia of MCF-7 under Near Infrared Radiation in the Presence of PEGylated Graphene Oxide Nanoparticles. Qualitative Analysis and Cytotoxic Activity of Ethanolic Extract of Piper betle Linn. Leaves: Induction of Apoptosis, Cell Cycle Arrest, and Caspase-3/7 Activation in HER2+ AU565 Breast Cancer Cell Line. Deciphering the Molecular Interactions of Tuberculosis and Colorectal Cancer: A Network and RNA-Seq Data Analysis Approach. In-Silico Identification of Natural Compounds as Dual Inhibitors of Aromatase and CDK4/6: A Multi-Target Approach for ER-Positive Breast Cancer Treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1